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OBJECTIVES: In the secondary prevention of cardio-
vascular disease patient compliance with established 
risk-reducing factors remains inadequate. The primary
objective of the ORBITAL Study is to evaluate the impact
of a compliance enhancing program in patients receiving
statin therapy on long-term disease-related outcomes and
costs. Here the design and results of the pilot phases are
presented. METHODS: Approximately 7000 patients 
eligible for statin therapy (Joint European Guidelines) will
be enrolled nationwide in primary care practices in
Germany. Patients will be randomised into an interven-
tion group (12-month rosuvastatin plus compliance
program) and a control group (12-month rosuvastatin
alone). Disease-related costs, quality of life, cardiovascu-
lar events, and compliance will be assessed every 6
months during the 36 months follow-up. The compliance
program was developed based on previous studies, expert
advice, and pilot testing, and includes a start package
with a video and an information brochure, followed by
mailings and telephone calls. The program addresses
factors such as diet and lifestyle in addition to compli-
ance with pharmacotherapy. The information brochure
and telephone calls were evaluated in two subsequent
pilot phases. RESULTS: In the ﬁrst pilot phase, 23 of 25
contacted patients in a cardiac rehabilitation center con-
sidered the brochure to be easy to understand although
some criticized the use of too many medical terms. 17%
of patients considered the brochure to be too long. In 
the second pilot phase, 70 patients were randomised 
into intervention (n = 37) or control (n = 33) groups. The
majority of the intervention patients expressed high sat-
isfaction with the telephone calls although 10% indicated
the calls contained too much information and should be
shortened. CONCLUSION: With regard to the compli-
ance initiatives evaluated, the importance of not over-
loading patients with information became apparent.
Therefore, the compliance enhancing program was
revised accordingly for the main phase of the ORBITAL
Study, which started in May 2002 and is scheduled to run
for 3 years.
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The chronic heart failure (CHF) is a chronic illness typi-
cally characterized by phases of clinical deterioration
requiring hospitalitation. The relief continuity is a fun-
damental element to better the effectiveness of the sani-
tary intervention. The Day-Hospital (DH), particularly,
could represent a valid tool to guarantee the relief conti-
nuity and to extend the phases of clinical stability in
patients with CHF. OBJECTIVES: The aim of this study
was to compare the managerial effectiveness and
Cost/Utility ratio between heart failure management
program delivered by day-hospital and usual care.
METHODS: Two hundred thirty-four consecutive
patients (M/F: 196/38; 56 ± 10 years) with chronic heart
failure (EF 29 ± 7%) referred to UHF were evaluated.
After clinical evaluation and therapuetic optimization,
122 patients received usual care (UC) and follow-up
(control every 6 months), despite 112 patients were acti-
vated in the DH. The DH program foresaw: 1) risk proﬁle
identiﬁcation; 2) objectives deﬁnition; 3) sanitary run
determination; 4) outcome markers measurement; and 5)
territory interaction (physician of family and/ or cardiol-
ogist of reference). Management (optimezed therapy and
Hospital readmission for heart failure (HRHF), func-
tional (NYHA functional class, Left ventricular ejection
fraction (LVEF)) and hard (cardiac death and urgent heart
transplantation) outcomes during 258 ± 88 days of
follow-up were considered. Cost/utility ratio of two
strategies were calculated. RESULTS: At baseline not
clinical and functional differences between two groups
were found. Hard cardiac events occured in 21/122
(17.2% on usual care (UC) and in 4/112 (3.6%) in DH
patients (p < .0007). The cost/utility ratio of two strate-
gies was similar (UC 2409$ vs DH $2244). The incre-
mental analysis pointed out for each gained Qaly in DH
a cost-saving of $1068. The cost-utility ratio for integra-
tion of Day Hospital to manage chronic heart failure was
$19,462(13,904–34,048). CONCLUSIONS: heart failure
management program delivered by day-hospital can
reduce mortality and morbidity of CHF patients. This
management strategy is cost-effective and has an equi-
table cost from a society point of view.
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